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Abstract 
Growth arrest‑specific protein 6 (Gas6) works synergistically with erythropoietin (EPO) to increase the proliferation and 
maturation of erythroblasts. However, the role of Gas 6 levels on EPO resistance in hemodialysis (HD) patients remains 
unclear. Therefore, the objective of this study was the first to examine the correlation between plasma Gas6 levels and 
EPO resistance in HD patients. We enrolled 134 HD patients and 85 healthy individuals. The HD patients were divided 
into 2 groups: 98 non‑EPO‑resistant patients and 36 EPO‑resistant patients. Plasma levels of Gas6, interleukin 6 (IL‑6), 
high‑sensitivity C‑reactive protein (hs‑CRP), and albumin were quantified. Compared with non‑EPO‑resistant patients, 
EPO‑resistant patients had elevated plasma concentrations of Gas6 (15.4 ± 3.3 vs. 13.7 ± 3.2 ng/mL, P = 0.006), IL‑6 
(3.1 ± 3.1 vs. 2.1 ± 1.5 pg/mL, P = 0.009), and hs‑CRP (12.7 ± 25.2 vs. 4.5 ± 5.5 mg/L, P = 0.002). In EPO‑resistant HD 
patients, plasma Gas6 levels were negatively correlated with albumin levels (r = −0.388, P < 0.021). Elevated Gas6 lev‑
els are associated with EPO resistance in HD patients. Also, EPO resistance is related to inflammation and malnutrition. 
Thus, circulating Gas6 levels could be used as the potential marker in HD patients with EPO resistance.
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Background
Erythropoietin (EPO) resistance is one of the most 
common complications in anemia patients undergoing 
hemodialysis (HD). Most factors causing EPO resist-
ance are associated with malnutrition, chronic inflam-
mation, hyperparathyroidism, and inadequate dialysis in 
HD patients, which shorten the lifespan of erythrocytes 
(Macdougall and Cooper 2002; Kanbay et al. 2010). EPO 
resistance is a potential risk factor for mortality, cardio-
vascular disease, and stroke, which are associated with 
the high-dose use of EPO-stimulating agents and inabil-
ity to achieve a target hemoglobin level (Kilpatrick et al. 
2008; Szczech et  al. 2008). Thus, a careful evaluation of 
EPO resistance is crucial in patient care for improving 
clinical outcomes.
Growth arrest-specific protein 6 (Gas6), a vitamin 
K-dependent protein, plays a role in cell growth, cell pro-
liferation, anti-inflammation, and phagocytosis (Tjwa 
et al. 2008; Ekman et al. 2010a, b). Gas6 is expressed in 
some cell types, such as endothelial, smooth muscle, 
and bone marrow cells (Tjwa et al. 2008). It was recently 
reported that elevated circulating Gas6 levels are corre-
lated with disease activity such as systemic inflammation 
(Ekman et al. 2010a, b), acute coronary syndrome (Jiang 
et  al. 2009), acute pancreatitis (Uehara et  al. 2009), and 
systemic lupus erythematosus (Ekman et  al. 2011). In 
chronic kidney disease patients, Gas6 levels were asso-
ciated with renal disease and inversely related to renal 
function, suggesting that Gas6 levels may serve as a bio-
marker for disease stage (Lee et al. 2012). In patients with 
critical limb ischemia, circulating Gas6 levels correlated 
with survival outcomes, indicating that Gas6 can be 
considered as a potential biomarker in clinical practice 
(Ekman et al. 2010a, b).
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In anemic mice, Gas6, released by erythroblasts, 
enhanced and synergized with EPO receptor signaling to 
facilitate hemoglobin synthesis (Angelillo-Scherrer et al. 
2008). However, to date, the correlation between Gas6 
and EPO resistance remains unclear in HD patients. 
Therefore, the objective of this study was the first to 
investigate the correlation between circulating Gas6 lev-
els and EPO resistance in HD patients.
Methods
Subjects
Healthy control and HD subjects were enrolled in this 
study at the Ping-Tung Christian Hospital. This study was 
approved by the human research ethics committee of the 
hospital (Approved No.: IRB171A), and informed con-
sent was obtained from each patient. Between Decem-
ber 2009 and December 2010, 85 healthy subjects were 
randomly recruited from an unselected population, as 
the control group. The experimental group included 134 
HD patients. Patients with sepsis, iron deficiency, folate 
deficiency, vitamin B deficiency, bone marrow diseases, 
and hematopoietic diseases were excluded from this 
study. The HD patients were further divided into two 
groups: EPO-resistant patients were defined as those 
receiving a high dose of EPO  ≥  40,000  U/month for a 
minimum of 6 months and with hematocrit (Hct) levels 
<33  %, and non-EPO-resistant patients were defined as 
those receiving a low dose of EPO < 40,000 U/month for 
a minimum of 6 months and with Hct levels >33 %. All 
patients underwent polysulfone HD 3 times/week (dialy-
sis flow of 500 mL/min for 4 h, endotoxin <0.03 EU/mL). 
After enrollment, fasting morning serum samples were 
obtained from the subjects and were stored at −80  °C 
until analysis.
Biochemical assessments were performed, including 
measurement of Gas6, interleukin 6 (IL-6), high-sensi-
tivity C-reactive protein (hs-CRP), blood urea nitrogen 
(BUN), albumin, phosphate, calcium, intact parathyroid 
hormone (i-PTH), Hct, ferritin, serum iron (SI), trans-
ferrin saturation (TSAT), total iron-binding capacity 
(TIBC), red blood cell (RBC) fragility, and Kt/V (product 
of dialyzer urea clearance and treatment time divided by 
body urea volume).
Measurement of growth arrest‑specific protein 6, interleukin 
6, and high‑sensitivity C‑reactive protein
Plasma Gas6 and IL-6 concentrations were determined 
using commercial enzyme immunoassay kits (R&D Sys-
tems, Minneapolis, MN), according to the manufacturer’s 
instructions (Yanagita et  al. 2002; Schuett et  al. 2009). 
Plasma hs-CRP levels were measured using a Beckman 
Coulter IMMAGE Immunochemistry System (Brea, CA) 
with a detection limit of 0.2  mg/L (Schuett et  al. 2009). 
The dilution curve was parallel to the standard curve. The 
inter- and intra-assay coefficients of variation were 8.0–
8.7 % and 3.4–7.1 % for Gas6 and 6.5–9.6 and 6.9–7.8 % 
for IL-6, respectively. Samples were measured in dupli-
cate in each experiment.
Measurement of serum biochemical parameters and red 
blood cell fragility
SI, TSAT, TIBC, BUN, albumin, phosphate, and calcium 
levels were measured with standard methods using Uni-
Cel DxC 800 (Beckman Coulter Inc., USA). Ferritin and 
i-PTH levels were measured using standard commer-
cial assays (Cobas e411, Roche Diagnostics, USA). Hct 
levels were measured using standard commercial kits 
(Sysmex XE-5000, Sysmex Corporation, Japan). TIBC 
(µmol/L) was calculated as plasma transferrin concen-
tration (g/L) × 1.4, and TSAT was calculated as the ratio 
of SI to TIBC (SI/TIBC). Urea clearance was expressed 
as Kt/V (K, dialyzer urea clearance; t, dialysis time; V, 
body urea volume), which is the measurement of dialysis 
adequacy. Kt/V values, calculated by Kt/V = Ln (Co/Ct) 
(Ln, natural logarithm; Co, postdialysis BUN; Ct, predi-
alysis BUN), expressed the changes in plasma BUN levels 
before and after HD. To evaluate RBC osmotic fragility, 
10 concentrations of NaCl, ranging from 0 to 0.9 %, were 
incubated with 50  µL of RBCs. The absorbance of the 
supernatant versus water was determined at 575  nm by 
using a spectrometer (µQuant, BioTek Instruments, Inc.). 
The NaCl concentration at which 50 % of the RBCs were 
lysed was considered as the median osmotic fragility (Wu 
et al. 1998).
Statistical analysis
Data are expressed as mean ± standard deviation. All sta-
tistical analyses were performed using Statistical Package 
for Social Science (SPSS for Windows, version 19.0; SPSS 
Inc., Chicago, IL). Statistical differences in variables were 
compared using the unpaired t test. Pearson correlation 
analysis was used to evaluate the bivariate relationship 
between individual variables and plasma Gas6 levels. A 
value of P ≤ 0.05 was considered statistically significant.
Results
Patient characteristics
The 85 control subjects comprised 33 healthy male 
and 52 healthy female subjects with an average age 
of 60.8  ±  10.8  years, and the 134 HD patients com-
prised 46 male and 88 female patients with an aver-
age age of 62.2 ±  13.3  years and an average HD period 
of 81.0  ±  39.9  months. The HD patients were further 
divided into 2 groups: (1) 36 EPO-resistant HD patients 
comprising 11 male and 25 female patients receiving 
a high dose of EPO ≥  40,000  U/month for a minimum 
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of 6 months and with Hct levels <33 %; and (2) 98 non-
EPO-resistant HD patients comprising 35 male and 63 
female patients receiving a low dose of EPO < 40,000 U/
month for a minimum of 6 months and with Hct levels 
>33 %.
Biochemical characteristics between normal 
and hemodialysis subjects
The clinical characteristics of the enrolled subjects are 
shown in Table  1. Compared with healthy subjects, 
HD patients had significantly higher concentrations of 
serum ferritin (453.9 ±  325.5 vs. 165.4 ±  110.0  ng/mL, 
P < 0.001), i-PTH (445.7 ± 502.8 vs. 26.4 ± 12.9 pg/mL, 
P < 0.001), phosphate (5.39 ± 1.48 vs. 3.59 ± 0.42 mg/dL, 
P < 0.001), plasma Gas6 (14.16 ± 3.28 vs. 6.65 ± 1.75 ng/
mL, P < 0.0001), IL-6 (2.35 ± 2.05 vs. 1.15 ± 1.89 pg/mL, 
P  <  0.001), and hs-CRP (6.7 ±  14.0 vs. 0.9 ±  0.9  mg/L, 
P  =  0.002). In contrast, compared with healthy sub-
jects, HD patients had significantly lower levels of SI 
(61.2  ±  23.0 vs. 91.3  ±  36.6  μg/dL, P  <  0.001), TIBC 
(252.6 ± 59.1 vs. 335.4 ± 62.9 μg/dL, P < 0.001), TSAT 
(25.4 ± 10.9 vs. 29.5 ± 17.3 %, P = 0.031), Hct (32.9 ± 2.5 
vs. 40.0 ± 3.9 %, P < 0.001), and albumin (3.97 ± 0.36 vs. 
4.56 ± 0.27 g/dL, P < 0.001).
Elevated growth arrest‑specific protein 6 and inflammation 
levels in erythropoietin‑resistant hemodialysis patients
A comparison of blood biochemistry data between the 
EPO-resistant and non-EPO-resistant HD patients is 
presented in Table 2. Compared with non-EPO-resistant 
patients, EPO-resistant patients had elevated concen-
trations of plasma Gas6 (15.4  ±  3.3 vs. 13.7  ±  3.2  ng/
mL, P  =  0.006), IL-6 (3.1  ±  3.1 vs. 2.1  ±  1.5  pg/mL, 
P = 0.009), and hs-CRP (12.7 ± 25.2 vs. 4.5 ± 5.5 mg/L, 
P  =  0.002). However, non-EPO-resistant patients had 
higher Hct concentrations than EPO-resistant patients.
Negative correlation between growth arrest‑specific 
protein 6 and albumin levels in erythropoietin‑resistant 
hemodialysis patients
A comparison of clinical variables associated with Gas6 
levels is presented in Table  3. In EPO-resistant HD 
patients, plasma Gas6 levels were negatively correlated 
with albumin levels (r = −0.388, P  <  0.021). Moreover, 
in healthy controls, Gas6 levels were positively correlated 
with IL-6 levels but negatively correlated with Hct and 
albumin levels.
Discussion and conclusions
Our study is the first to demonstrate that EPO-resistant 
HD patients have higher Gas6 levels than non-EPO-
resistant HD patients. Our results showed that elevated 
circulating Gas6 levels were associated with EPO resist-
ance in HD patients. In addition to Gas6 levels, con-
centrations of inflammation markers, s uch as IL-6 and 
hs-CRP, were increased in EPO-resistant HD patients. 
Further analyses showed that circulating Gas6 levels 
Table 1 Clinical characteristics of study subjects
Data are mean ± SD
SI serum iron, TSAT transferring saturation, TIBC total iron-binding capacity, 
i-PTH intact parathyroid hormone, Gas6 growth arrest-specific protein 6, IL-6 
Interleukin 6, Hs-CRP high sensitivity C-reactive protein, RBC red blood cell




Ferritin (ng/ml) 165.4 ± 110.0 453.9 ± 325.5 <0.001
SI (μg/dl) 91.3 ± 36.6 61.2 ± 23.0 <0.001
TSAT (%) 29.5 ± 17.3 25.4 ± 10.9 0.031
TIBC (μg/dl) 335.4 ± 62.9 252.6 ± 59.1 <0.001
i‑PTH (pg/ml) 26.4 ± 12.9 445.7 ± 502.8 <0.001
Hematocrit (%) 40.0 ± 3.9 32.9 ± 2.5 <0.001
Albumin (g/dl) 4.56 ± 0.27 3.97 ± 0.36 <0.001
Phosphate (mg/dl) 3.59 ± 0.42 5.39 ± 1.48 <0.001
Calcium (mg/dl) 9.18 ± 0.37 9.33 ± 0.87 0.136
Gas6 (ng/ml) 6.65 ± 1.75 14.16 ± 3.28 <0.001
IL‑6 (pg/ml) 1.15 ± 1.89 2.35 ± 2.05 <0.001
hs‑CRP (mg/l) 0.9 ± 0.9 6.7 ± 14.0 0.002
RBC fragility test (% of 
NaCl)
0.426 ± 0.034 0.414 ± 0.049 0.075
Table 2 A comparison of  blood biochemistry data 
between  the EPO-resistant and  non-EPO-resistant HD 
patients
Data are mean ± SD
EPO erythropoietin, SI serum iron, TSAT transferring saturation, TIBC total iron-
binding capacity, i-PTH intact parathyroid hormone, Gas6 growth arrest-specific 
6, IL-6 Interleukin 6, Hs-CRP high sensitivity C-reactive protein, RBC red blood cell
Item Non‑EPO resistance EPO resistance P value
N 98 36
Ferritin (ng/ml) 445.4 ± 330.8 472.9 ± 310.0 0.668
SI (μg/dl) 62.6 ± 22.3 57.8 ± 24.8 0.293
TSAT (%) 25.6 ± 11.2 24.5 ± 10.0 0.618
TIBC (μg/dl) 257.7 ± 58.0 241.4 ± 64.0 0.167
i‑PTH (pg/ml) 417.7 ± 460.0 514.0 ± 609.0 0.331
Hematocrit (%) 33.5 ± 2.4 31.3 ± 2.7 <0.001
Albumin (g/dl) 4.0 ± 0.3 3.9 ± 0.4 0.173
Phosphate (mg/dl) 5.3 ± 1.5 5.6 ± 1.5 0.233
Calcium (mg/dl) 9.4 ± 0.8 9.2 ± 0.9 0.224
Gas6 (ng/ml) 13.7 ± 3.2 15.4 ± 3.3 0.006
IL‑6 (pg/ml) 2.1 ± 1.5 3.1 ± 3.1 0.009
hs‑CRP (mg/l) 4.5 ± 5.5 12.7 ± 25.2 0.002
Kt/V 1.79 ± 0.29 1.73 ± 0.32 0.272
RBC fragility test (% of 
NaCl)
0.413 ± 0.05 0.417 ± 0.04 0.700
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were negatively correlated with albumin levels in EPO-
resistant HD patients. Elevated circulating Gas6 levels 
may serve as a clinical marker for EPO resistance in HD 
patients.
In our study, circulating Gas6 levels were elevated in 
EPO-resistant HD patients. Our data are consistent with 
the results of recent studies. Studies show that circulat-
ing Gas6 levels are associated with disease activity, such 
as severe sepsis (Borgel et al. 2006) or septic shock (Gibot 
et al. 2007), acute coronary syndrome (Jiang et al. 2009), 
and glomerular injury in nephrotoxic nephritis (Yanagita 
et  al. 2002). Moreover, elevated Gas6 levels were asso-
ciated with increased mortality in patients with severe 
peripheral arterial disease, characterized by rest pain and 
gangrene in the legs (Ekman et al. 2010a, b). In chronic 
kidney disease patients, Gas6 levels increased with kid-
ney disease stage progression and were inversely related 
to the estimated glomerular filtration rate (P  <  0.0001). 
In mouse models, Gas6 enhanced EPO receptor signal-
ing stimulating hemoglobin production, thus playing 
the role of a hemoglobin regulator (Angelillo-Scherrer 
et al. 2008). In our study, thus we observed that a clinical 
marker associated with EPO resistance in HD patients 
were linked to circulating Gas6 levels.
In addition to circulating Gas6 levels, plasma IL-6 and 
hs-CRP levels were significantly higher in EPO-resistant 
patients than in non-EPO-resistant patients. Some other 
studies have also reported elevated IL-6 and hs-CRP lev-
els in EPO-resistant HD patients (Abe et  al. 2011a, b; 
Shinzato et al. 2008). This indicates that EPO resistance is 
linked to systemic inflammation in HD patients. Recently, 
Gas6 was proposed to be a potential regulator of immune 
response in the development of systemic inflammation 
(Yanagita et al. 2002; Borgel et al. 2006; Hurtado and de 
Frutos 2010). In mouse models of inflammation, Gas6 
induced the sequestration of circulating platelets and leu-
kocytes on activated endothelium to form circulating leu-
kocyte-platelet conjugates, resulting in thrombosis and 
inflammation (Tjwa et  al. 2008). Moreover, it is known 
that inflammatory cytokines, such as hs-CRP, IL-6, and 
tumor necrosis factor-α, suppress erythropoiesis, result-
ing in inadequate response to recombinant human EPO 
treatment (Abe et al. 2011a, b; Shinzato et al. 2008; Goi-
coechea et  al. 1998; Kalantar-Zadeh et  al. 2004). In our 
study, Hct levels were significantly lower in EPO-resist-
ant HD patients than in non-EPO-resistant HD patients 
(31.3 vs. 33.5 %, P < 0.001).
Furthermore, plasma Gas6 levels were negatively cor-
related with serum albumin levels (r = −0.388, P < 0.021) 
in EPO-resistant HD patients, implying that EPO resist-
ance could be linked to nutritional status. Recently, Lee 
et al. (2012) reported that higher Gas6 levels were asso-
ciated with low albumin levels in chronic kidney disease 
patients, suggesting a possible connection between mal-
nutrition and inflammation associated with worsening 
renal function. Moreover, resistance to EPO treatment 
was associated with low albumin levels in HD patients 
with depression (Afsar 2013). Furthermore, a lower 
response to EPO treatment was observed in diabetic HD 
patients with malnutrition-inflammation-atherosclerosis 
Table 3 A comparison of clinical variables associated with Gas6 levels
The correlations were estimated using the Pearson correlation test
Gas6 growth arrest-specific 6, EPO erythropoietin, SI serum iron, TSAT transferring saturation, TIBC total iron-binding capacity, i-PTH intact parathyroid hormone, Hct 
hematocrit, IL-6 Interleukin 6, Hs-CRP high sensitivity C-reactive protein, EPO erythropoietin
Item Healthy control (N = 85) Non‑EPO resistance (N = 98) EPO resistance (N = 36)
Variable r P value r P value r P value
Ferritin 0.022 0.845 −0.140 0.167 −0.206 0.236
SI −0.192 0.078 −0.060 0.558 −0.148 0.395
TSAT −0.117 0.287 −0.09 0.373 −0.154 0.378
TIBC −0.018 0.871 0.067 0.508 0.068 0.699
i‑PTH 0.043 0.694 0.139 0.171 0.056 0.748
Hematocrit −0.248 0.022 0.141 0.164 −0.174 0.318
Albumin −0.320 0.003 −0.096 0.343 −0.388 0.021
Phosphate 0.034 0.756 −0.116 0.254 −0.172 0.322
Calcium −0.042 0.704 −0.003 0.977 0.043 0.805
IL‑6 0.321 0.003 −0.043 0.675 0.149 0.393
hs‑CRP 0.066 0.546 −0.017 0.868 0.013 0.941
Kt/V – – −0.065 0.524 0.300 0.081
EPO dose – – −0.118 0.244 −0.151 0.387
Page 5 of 6Chen et al. SpringerPlus  (2016) 5:29 
syndrome (Abe et al. 2011a, b). Overall, EPO resistance is 
expected to be associated with nutritional and inflamma-
tion status (Bamgbola et al. 2009).
RBC fragility could be augmented by inadequate dialy-
sis, which modifies cell membrane structure and shortens 
RBC lifespan (Stenvinkel and Barany 2002; Sotirako-
poulos et al. 2004). In our study, RBC fragility levels and 
Kt/V values did not significantly differ between EPO-
resistant and non-EPO-resistant HD patients, indicating 
adequate dialysis in both groups. Moreover, serum fer-
ritin levels were adequate and did not significantly differ 
between the two groups. Sepsis, folate deficiency, vitamin 
B deficiency, bone marrow diseases, and hematopoietic 
diseases were not considered as factors causing EPO 
resistance in HD patients. The exclusion of these fac-
tors could have strengthened our study to demonstrate 
an association between circulating Gas6 levels and EPO 
resistance in HD patients.
In conclusion, ours is the first study to show elevated 
circulating Gas6 levels in EPO-resistant HD patients. 
Compared with non-EPO-resistant HD patients, EPO-
resistant HD patients had significantly increased con-
centrations of plasma Gas6, IL-6, and hs-CRP. Moreover, 
circulating Gas6 levels were negatively correlated with 
albumin levels in EPO-resistant HD patients. Thus, EPO 
resistance in HD patients is associated with inflamma-
tion and nutritional status. Circulating Gas6 levels might 
be used as a potential biomarker for EPO resistance in 
HD patients. However, the cross-sectional design of our 
study was a limitation, and therefore, the relevance of 
these findings needs to be further investigated in longitu-
dinal cohort studies.
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